More than half of patients are denied approval for PCSK9i, study finds

More than half of patients are denied approval for proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), according to research published in the journal Circulation. And that’s true even though many appear to meet labeled indicators, the data shows. “Although a combination of clinical characteristics increases the likelihood of approval, payer type is the most significant […]

GHLF recently worked with the University of Michigan’s Center for Value Based Insurance Design (V-BID) on a report about Copayment Assistance Programs.